Drug Database
DI

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine (KD370 / KD 370 / Quintovac)

✓ Approved

Meiji Holdings · Vaccine · Vaccine

What is diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine?

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine is a vaccine developed by Meiji Holdings. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesKD370, KD 370, Quintovac
CompanyMeiji Holdings
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Meiji Holdings

Therapeutic Indications

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved
Surgical and medical proceduresPolio immunisation✓ Approved

Related Research Articles

PubMedVaccine2026-05-24

Improving Tdap vaccine uptake during pregnancy: a five-year analysis at a regional center.

Perry Bryce Nicole V NV, Marrero Arocho Maria De L ML, Seybold Dara D, Calhoun Byron B

To evaluate tetanus, diphtheria, and acellular pertussis (Tdap) vaccination rates among pregnant patients before, during, and after the COVID-19 pandemic and identify demographic and care-related factors associated with vaccine uptake at our tertiary-care medical center in Southern West Virginia. We conducted a retrospective cohort study of pregnant patients age 18 years or older with viable pregnancies through 36 weeks of gestation from January 11, 2019, to June 30, 2024 at a single tertiary-care medical center. Patients were categorized into pre-COVID-19, during-COVID-19, and post-COVID-19 cohorts. Vaccination uptake was analyzed using ANOVA, and additional bivariate analyses were conducted to identify demographic and clinical factors associated with Tdap receipt during pregnancy. Among 2513 patients, 1705 (67.8%) received Tdap vaccination, which was higher than the national average of 56.6% in 2022-2023. Vaccination rates did not differ across 3 different phases relative to the COVID-19 pandemic (p = .97). Tdap vaccination was more common among patients who were married as compared with unmarried patients (70.4% vs 65.8%, p = .016), white versus non-white patients (68.9% vs 62.5%, p = .011), and patients receiving care in private-practice-based clinics versus hospital-based clinics (76.6% vs 65.6%, p < .001). No statistically significant difference was noted when stratified by insurance type (p = .24) or advanced maternal age (≥35 years) (p = .35). Tdap vaccination rates at our institution exceeded national averages and remained stable throughout the COVID-19 pandemic. Persistent disparities by race, marital status, and care setting highlight vaccination inequities and support the need for targeted interventions for patient and provider sub-groups.

PMID 42177158
Read full article →
PubMedEconomics and human biology2026-05-24

Heterogeneous returns to antenatal care: Evidence from childhood immunization in Senegal.

Kolani Tadandjoa T

Antenatal care (ANC) serves both as a medical input and as a source of health information in the child health production function. We use seven waves of the Senegal Demographic and Health Surveys, matched to regional health-facility data, to estimate the effect of ANC adherence on childhood vaccination outcomes. We address endogeneity arising from unobserved heterogeneity in ANC utilization using a two-stage copula-based control-function approach. We find that ANC adherence has no effect on the composite measure of full immunization, but significantly increases uptake of two injectable vaccines, the three-dose diphtheria-pertussis-tetanus vaccine (DTP3) and measles, by 8.2 % and 6.3 % points, respectively. These effects are concentrated among mothers with no schooling or only primary education. We also find no robust evidence that the marginal returns to ANC adherence differ by child sex, fertility intention, or ethnicity.

PMID 42176395
Read full article →
PubMedJournal of experimental & clinical cancer research : CR2026-05-24

Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma.

Tazzari Marcella M, Carloni Silvia S, Bulgarelli Jenny J, Pignatta Sara S et al.

Dendritic Cell Vaccines (DCVax) can induce tumor-specific immune responses, yet their clinical activity remains limited and poorly understood. We sought to identify cellular and molecular features within the vaccine product that are associated with clinical response to monocyte-derived DC vaccines in metastatic melanoma. We performed a multi-omics analysis integrating multiparametric flow cytometry, single-cell RNA sequencing of DCVax products, transcriptomic profiling of CD14⁺ monocytes from apheresis, and in situ characterization of pre-treatment melanoma biopsies. Patients were stratified into Responders (Rs) or Non-Responders (NRs) based on best overall response and Delayed-Type Hypersensitivity (DTH) status. An unanticipated population of CD19⁺ plasmablast-like B cells was identified within the final DCVax products. These B cells, phenotypically distinct from their circulating precursors, were significantly enriched in Rs and mirrored a B-cell-inflamed baseline state characterized by mature Tertiary Lymphoid Structures (mTLS) in pre-treatment tumor lesions. While mature LAMP3⁺ DCs appeared at comparable frequencies across outcomes, LAMP3⁺ DCs from Rs selectively upregulated HSPA1A/B, consistent with enhanced antigen-processing programs. Transcriptomic signatures of antibody production in vaccine-resident B cells, together with Fc receptor expression on DCs, support a model in which B-cell activity may contribute to antigen loading and DC functional tuning during vaccine manufacturing, a hypothesis that warrants functional validation. Our findings reveal a previously unrecognized B-cell component of DCVax biology, suggesting that cooperative DC-B-cell interactions, combined with baseline B-cell/mTLS features, may contribute to shaping vaccine immunogenicity. While causality cannot be established from the present data, these insights offer actionable avenues for enhancing both vaccine manufacturing and patient selection, extending beyond melanoma.

PMID 42177548
Read full article →
PubMedVaccine2026-05-24

Consultation report - gonococcal immunoassays and standards for vaccine development.

MacLennan C A CA, Davis P P, Gottlieb S L SL, Seib K L KL et al.

Gonorrhoea is a sexually transmitted infection with adverse outcomes for sexual, reproductive and neonatal health. Additionally, the bacterium, Neisseria gonorrhoeae, has demonstrated increasing resistance against multiple classes of antimicrobials, making combatting gonorrhoea a priority for the World Health Organization. An effective vaccine would have substantial global public health benefit and a major impact on the silent pandemic of antimicrobial resistance. Several candidate gonococcal vaccines, representing a number of vaccine platforms, are in pre-clinical development. In addition, a number of clinical studies are underway to assess the efficacy of the meningococcal group B vaccine, 4CMenB, against gonorrhoea. A major challenge in comparing gonococcal vaccine candidates and vaccine-induced immune responses is the lack of standardised and harmonised immunoassays. At present, immunogenicity of the different vaccine formulations is measured through assays which have been developed independently in different laboratories. As the development of candidate gonococcal vaccines moves into clinical trials, improved harmonisation in the measurement of immunogenicity is key for comparing vaccine responses across trials. This requires international standards, including an international serum standard for gonococcal immunoassays, and a panel of standard target strains, which are currently lacking. A further complication is the lack of knowledge about immune correlates of protection against gonorrhoea, and, therefore, the most appropriate assays to use to assess the immune response to a candidate vaccine. As further data are gathered from clinical studies exploring protection against gonorrhoea provided by 4CMenB, it may be possible to discern correlates of protection, but this also requires standardised assays. A workshop was held at Keble College, Oxford, United Kingdom in April 2024, with participation from vaccine developers, regulators and assay standardisation specialists. Its goal was to advance discussions on gonococcal immunoassay standardisation priorities, including generation of a gonococcal international reference serum. The meeting discussion, outcomes and recommendations are outlined in this report.

PMID 42176439
Read full article →
PubMedFish & shellfish immunology2026-05-24

Evaluation of the Immunological Efficacy of EsxA Subunit Vaccine and DNA Vaccine against Streptococcus iniae in golden pompano (Trachinotus anak).

Huang Zhiyuan Z, Sun Heng H, Wang Haoyu H, Jia Xinlei X et al.

Streptococcus iniae represents an important bacterial agent responsible for streptococcosis in marine fish, leading to substantial economic impacts in aquaculture worldwide. The development of effective vaccines is therefore a critical priority. EsxA, a conserved early-secreted and homolog of antigenic target six (ESAT-6), is involved in bacterial virulence and mediates interactions between the pathogen and its host via the type VII secretion system. In this work, EsxA was examined as a prospective vaccine antigen in golden pompano (Trachinotus anak) using both subunit and DNA vaccination strategies. Recombinant EsxA protein was expressed in Escherichia coli BL21(DE3) and administered intraperitoneally as a subunit vaccine, either alone or formulated with the oil-based adjuvant Montanide ISA 763A. Concurrently, a DNA vaccine was developed by cloning the complete esxA gene into the pVAX1 vector. Vaccinated fish were subjected to challenge with S. iniae at 8 weeks post-immunization to evaluate protective efficacy and assess the host's innate and adaptive immune responses. A high level of protection against S. iniae challenge was achieved with the EsxA-based subunit vaccine, particularly when formulated with adjuvant ISA 763A, whereas the DNA vaccine elicited moderate yet statistically significant protection. Immunological profiling revealed robust antigen-specific IgM production following subunit vaccination, while DNA vaccination significantly upregulated transcription of key immune-related genes associated with antigen presentation and cellular immunity, including MHC class I and CD8α. Furthermore, nonspecific immune parameters, including catalase, lysozyme, acid phosphatase, alkaline phosphatase activity and superoxide dismutase, were significantly elevated following vaccination, indicating potent activation of innate immune defense. Collectively, EsxA is a promising vaccine candidate against S. iniae in T. anak, and different vaccine platforms elicit distinct immune response profiles that may inform future vaccine optimization in marine aquaculture.

PMID 42176785
Read full article →
PubMedVaccine2026-05-24

Evaluation of EcoCRM, virus-like particles, and mRNA as vaccine platforms against Borrelia burgdorferi.

Rocuskie-Marker Carleena M CM, Huckaby Annalisa B AB, Conaway Olivia M OM, Pyles Gage M GM et al.

Lyme disease (LD) is the most prevalent vector-borne disease in the United States, impacting ∼476,000 individuals annually with increasing incidence. Prevention relies on personal protective measures such as insecticides and tick checks, underscoring the need for new preventatives such as vaccines. In this work, the importance of vaccine platform in LD vaccine development efforts was evaluated using non-lipidated OspA as model antigen. Recombinant OspA conjugated to CRM197 (EcoCRM OspA), a virus-like particle vaccine utilizing SpyTag and SpyCatcher (OspA-SpyVLP), and an mRNA-based vaccine construct (OspA mRNA) were evaluated and compared in C3H mice using the needle injection challenge model. To determine immunogenicity, anti-OspA and anti-B. burgdorferi antibodies were quantified via ELISA and further assessed by measuring IgG subclass, antibody avidity, and presence of antibody secreting cells. All vaccine formulations were immunogenic and led to the release of similar levels of antigen-specific IgG in serum during the duration of the experiment. However, there were significant differences around two week post-boost in the presence of antibody secreting cells, ratio of IgG1/IgG2 subclasses, and antibody avidity between platforms. Protection was measured using PCR and darkfield microscopy to determine organ positivity post-challenge. Vaccination with recombinant non-lipidated OspA and OspA-SpyVLP significantly reduced the number of positive organs compared to the PBS challenged control group. Lastly, in vitro borreliacidal activity was quantified via darkfield microscopy and the highest borreliacidal activity was observed using OspA-SpyVLP sera, with titers 16-fold higher than recombinant OspA. Altogether, these data indicated that selection of vaccine platform/formulation influenced the immunogenicity and efficacy of OspA-based LD vaccines and should be considered during development.

PMID 42176436
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine